Is It Legal to Sell Peptides in New York: A Founder's Operating Guide

Running a research peptide brand is already a high-stakes compliance exercise at the federal level. When you add New York to the picture, either because your business is incorporated there, your warehouse sits there, or a meaningful share of your orders ship there, the stakes climb again. New York has its own drug registration statute, section 6808 of its Education Law, and it is worth reading directly. The fear behind most New York questions is simple: am I operating illegally right now, and do I even know it?

The short answer: federal law decides whether your product is a drug by its intended use, and New York adds a registration law for anyone who sells or wholesales drugs. Intended use is not read from the label alone. Federal regulation 21 CFR 201.128 says intent can be shown by "labeling claims, advertising matter, or oral or written statements by such persons or their representatives," so your website, emails and customer service answers count too. New York Education Law section 6808 says: "No person, firm, corporation or association shall possess drugs, prescriptions or poisons for the purpose of compounding, dispensing, retailing, wholesaling, or manufacturing, or shall offer drugs, prescriptions or poisons for sale at retail or wholesale unless registered by the department as a pharmacy, wholesaler, manufacturer or outsourcing facility." If you sell into or from New York, ask a New York attorney whether that statute applies to your products. The rest of this guide walks through both layers in the depth you need to have an informed conversation with a New York attorney before you make a single operational decision.

Why Federal Intended-Use Law Is the Starting Gate

Before New York's registration question even becomes relevant, you have to answer a prior question: is the product a drug under federal law? The New York drug registration statute is written about drugs, so the answer matters for whether it applies to your product.

Whether a product is a drug under federal law is a question for your attorney. The word "intended" matters here, and 21 CFR 201.128 addresses what intended uses refer to.

21 CFR 201.128, which you can read at ecfr.gov, states: "The words intended uses or words of similar import ... refer to the objective intent of the persons legally responsible for the labeling of an article (or their representatives)." That phrase "objective intent" is the part that founders consistently underestimate. The regulation says: "This objective intent may, for example, be shown by labeling claims, advertising matter, or oral or written statements by such persons or their representatives." It also says: "The intent may be shown by such persons' expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article." Review your website copy, your social media posts, your email sequences, and your customer service language against that text with your attorney.

This is why you should not treat a "research use only" label as settling anything by itself. FDA's Peptide Partners warning letter states: "evidence obtained from your website establishes that your products are intended to be drugs for human use". We cover the mechanics of this in much more detail in our guide on what "research use only" actually means, and we recommend reading it alongside this article.

The practical implication for New York is direct. Section 6808 is written about drugs. Ask your attorney whether your products are drugs under federal law, and if so how section 6808 applies to your operations. The sequence matters: federal characterization first, then state registration analysis.

What New York Education Law Section 6808 Actually Says

New York Education Law section 6808, subdivision 1, contains the core prohibition that every founder selling into or from New York needs to read. The statute states:

"No person, firm, corporation or association shall possess drugs, prescriptions or poisons for the purpose of compounding, dispensing, retailing, wholesaling, or manufacturing, or shall offer drugs, prescriptions or poisons for sale at retail or wholesale unless registered by the department as a pharmacy, wholesaler, manufacturer or outsourcing facility."

Read that sentence carefully. It covers two distinct triggers. The first trigger is possession for the purpose of compounding, dispensing, retailing, wholesaling, or manufacturing. The second trigger is offering drugs for sale at retail or wholesale. You do not have to complete a transaction to be within the scope of the second trigger. Offering for sale is enough. If your website lists a product, accepts orders, and ships to New York addresses, and that product is characterized as a drug by its intended use, ask your attorney whether that counts as offering it for sale in New York.

The statute refers to registration "by the department". Ask your attorney which agency handles registration and how. The categories of registration the statute contemplates are pharmacy, wholesaler, manufacturer, and outsourcing facility. For a research peptide brand that is not compounding, not dispensing to patients, and not operating as a retail pharmacy, which registration category, if any, applies depends on your operational model. That is a legal question, not an operational one, and it requires a New York attorney who practices in this area.

What the statute does tell us clearly is the fee associated with a wholesaler or manufacturer registration application. The application is accompanied by a fee of eight hundred twenty-five dollars. This guide quotes only the application fee, and the statute may set other fees, so do not treat that figure as the total cost of registration. There may be other costs, including legal fees, compliance costs, and operational changes, that your attorney will help you anticipate.

Section 6808-b and Nonresident Sellers

If your business is located outside New York but you ship orders to New York customers, your analysis does not stop at section 6808. New York Education Law section 6808-b covers the registration of nonresident establishments. This guide does not describe section 6808-b, so read it directly. What we will say is this: if you are a seller located outside New York, you should read section 6808-b carefully and bring it to your attorney's attention as a specific item for discussion. Ask your attorney whether being incorporated or warehousing in another state changes the analysis.

Other states may have their own rules. We have written guides for each of those states at Is it legal to sell peptides in Florida?, Is it legal to sell peptides in California?, and Is it legal to sell peptides in Texas?. The New York nonresident provision is worth understanding in the same comparative context.

The Intended-Use Problem in Operational Practice

Let us work through how the intended-use analysis plays out in a real operational scenario, because the abstract legal principle becomes much more concrete when you apply it to the decisions you are making every day as a founder.

Example: Imagine a brand that sells a peptide compound. The product page uses no health claims. The label says "for research use only, not for human use." The founder believes the product is clearly positioned as a research chemical. But the brand also runs an email list. In one of those emails, the copywriter described the compound in terms that referenced a physiological process in the human body. The brand also reshared a post from a social media account that described the compound in terms of a personal experience. The brand's customer service team, when asked by a customer whether the product was "safe to use," responded with information about the compound's properties rather than redirecting to a researcher or declining to answer.

Under that same regulation, the email and the customer service response are statements by the brand, so ask your attorney how they would be read. Neither of them is on the label.

Now apply that to New York. Section 6808 speaks of offering drugs for sale at retail or wholesale unless registered. Ask your attorney whether this brand would be doing that, and whether the label, the "research use only" language, or the brand's own communications change the answer.

Facts like these are why you should have your intended-use position reviewed. The solution is not to panic. The solution is to build your operations around a defensible intended-use position from day one, and to have a New York attorney review your specific situation before you make decisions about registration, entity structure, and market access.

For a deeper treatment of the intended-use framework at the federal level, see our guide on whether it is legal to sell peptides online and our overview of whether you need a license to sell peptides.

Ordinary Business Setup in New York

Separate from the drug registration question, ask your attorney and accountant which standard formation and tax registration steps apply to your business. These are not peptide-specific questions. We are covering them here because founders sometimes conflate the drug registration question with the general business formation question, and they are distinct processes handled by distinct agencies.

Forming your entity

Entity filings in New York go to the New York Department of State. For a limited liability company, New York Limited Liability Company Law section 203 refers to "the filing of the initial articles of organization with the department of state". Ask your attorney which filings apply if you are forming a corporation or registering an out of state entity. The choice of entity type has tax, liability, and operational implications that your attorney and accountant should help you work through. Whether your ecommerce activity counts as "doing business" in New York is another question for your attorney. Check the official New York state websites for current fees and processing times.

Registering for sales tax

Sales tax registration is handled by the New York State Department of Taxation and Finance. Its registration page says: "Certain sellers of taxable property or services are subject to a presumption that they are sales tax vendors who are required to register and collect state and local sales taxes." The application is for a sales tax Certificate of Authority. Ask your accountant whether you must register before you make taxable sales. Whether your specific products are taxable, whether you have nexus in New York, and when your registration obligation is triggered are all questions that depend on your specific facts. Your accountant or tax attorney should advise you on those questions. What we can say as a general operational matter is that you should not wait until after you have made sales to address this. Raise this question before you begin making sales, not after.

Treat the sales tax question and the drug registration question as separate questions. Both need to be addressed.

For a broader look at the state-level licensing landscape across multiple states, our guide on peptide state business licensing is a useful reference point.

Building a Defensible Intended-Use Position

Because the intended-use determination is the hinge on which everything else turns, it is worth spending real time on what a defensible intended-use position looks like operationally. This is not a legal standard we are setting. It is an operational framework for thinking about the decisions you make every day.

A defensible intended-use position starts with your product catalog. Every product you sell should have a clearly documented basis for its research classification. That means you should be able to articulate, in writing, why this compound is sold for research purposes, who the research customer is, and what the research application is. That documentation is not just for regulators. It is for your team, your customer service representatives, your marketing contractors, and anyone else who touches the product.

Your website copy is the next layer. Every product description, every category page, every blog post, and every FAQ on your site should be reviewed against the intended-use standard. The question to ask for every piece of copy is: does this communicate a human health outcome, a physiological effect in a human body, or a use case that implies human consumption? If the answer is yes, take that copy to your attorney. Ask whether a disclaimer near it changes the answer.

Your email marketing is a layer that founders frequently overlook. Email sequences, promotional campaigns, and even transactional emails can contain language that creates an intended-use problem. Your email marketing team needs to understand the standard and apply it consistently.

Your social media presence is another layer. This includes not just what you post, but what you reshare, what you comment on, and what accounts you follow or amplify. A brand that consistently engages with content about human health outcomes should ask its attorney how that engagement could be read, even if none of that content appears on the brand's own product pages.

Your customer service protocols are the final layer we will address here. Customer service representatives need clear written protocols for how to respond to questions about human use, health outcomes, and physiological effects. The protocol should be to decline to answer those questions and to redirect the customer to a qualified researcher or physician. That protocol should be documented, trained, and audited.

None of these operational steps substitute for legal advice. They are the operational hygiene that makes your legal position defensible. Your attorney will tell you what the legal standard requires. Your operations team executes against that standard every day.

The Decision Procedure for New York Operations

The following is a numbered decision procedure for founders evaluating their New York exposure. Each step has a pass or fail check. This procedure is not a substitute for legal advice. It is a structured way to organize your thinking before you talk to an attorney.

Step 1: Characterize your product under federal intended-use law.

Work through the intended-use analysis for each product in your catalog. Review your website copy, your email marketing, your social media presence, and your customer service records. Ask: does the totality of how we present this product communicate a human health use?

Pass: You can document a clear, consistent research-use positioning across all customer-facing materials, with no human health claims, no physiological outcome language, and no customer service responses that imply human use.

Fail: Any customer-facing material, including email, social media, or customer service records, contains language that could be read as communicating a human health use.

If you fail Step 1, stop and engage a New York attorney before proceeding. The downstream steps assume you have a defensible intended-use position. If you do not, the downstream steps are premature.

Step 2: Determine whether your product is a drug under federal law.

This is a legal determination, not an operational one. Based on your Step 1 analysis, and with input from a qualified attorney, determine whether your product is characterized as a drug under the Food, Drug, and Cosmetic Act.

Pass: Your attorney advises that your product, as currently positioned and marketed, is not a drug under federal law.

Fail: Your attorney advises that your product is, or may be, characterized as a drug under federal law.

If you fail Step 2, the New York drug registration analysis is directly relevant to your operations. Proceed to Step 3 with that understanding. If you pass Step 2, keep your attorney's written reasoning on file, revisit it whenever your labeling or marketing changes, and go to Step 6.

Step 3: Determine whether New York Education Law section 6808 applies to your operations.

With your attorney, analyze whether your activities, specifically possessing the product for the purpose of wholesaling or retailing, or offering it for sale in New York, bring you within the scope of section 6808.

Pass: Your attorney advises that section 6808 does not apply to your specific products and operations.

Fail: Your attorney advises that section 6808 applies, or that the question is close enough to require registration as a risk management decision.

If you fail Step 3, proceed to Step 4. If you pass Step 3, go to Step 6.

Step 4: Determine which registration category applies.

With your attorney, determine whether the wholesaler, manufacturer, pharmacy, or outsourcing facility registration category is the appropriate one for your operational model.

Pass: Your attorney identifies the correct registration category and confirms that you meet the eligibility requirements for that category.

Fail: Your attorney identifies a registration category but advises that your current operations do not meet the eligibility requirements, or that registration would require operational changes you are not prepared to make.

If you fail Step 4, you have a business model decision to make before you can proceed. Make that decision with your attorney and, if relevant, your accountant. If you pass Step 4 and are located outside New York, go to Step 5; otherwise go to Step 6.

Step 5: If you are located outside New York, analyze section 6808-b.

Ask your attorney to review section 6808-b specifically in the context of your nonresident operations. Determine whether a separate nonresident registration is required.

Pass: Your attorney advises that section 6808-b does not require a separate nonresident registration for your operations.

Fail: Your attorney advises that a separate nonresident registration is required and that you do not currently have it.

If you pass Step 5, go to Step 6. If you fail Step 5, address the nonresident registration before continuing to ship to New York.

Step 6: Complete standard business formation and tax registration.

Confirm with your attorney and accountant that your entity formation and any required tax registration are complete before making sales.

Pass: Both registrations are complete and current.

Fail: Either registration is missing or lapsed.

If you fail Step 6, complete the missing registrations before making sales in New York.

Step 7: Audit your ongoing compliance.

Compliance is not a one-time event. Schedule a regular audit of your customer-facing materials, customer service records, and operational practices against the intended-use standard and any registration conditions.

Pass: You have a documented audit schedule, a responsible team member assigned to each audit, and a record of completed audits.

Fail: You have no documented audit process.

If you fail Step 7, build the audit process before you consider your New York compliance posture complete.

Questions to Take to a New York Attorney

One of the most common mistakes founders make is going to an attorney without a prepared list of specific questions. A general conversation about "peptide law in New York" is expensive and often inconclusive. A focused conversation built around specific questions about your specific operations is far more productive. The following list is designed to give you a starting point.

Before your attorney meeting, prepare a one-page summary of your operations that covers: the products you sell, how they are labeled, how they are marketed, where your warehouse or fulfillment center is located, where your entity is formed, and the approximate volume of orders you ship to New York addresses each month. Bring that summary to the meeting along with this question list.

Questions about product characterization:

1. Based on our current product labeling, website copy, email marketing, and customer service protocols, do you believe our products are characterized as drugs under 21 CFR 201.128 and the Food, Drug, and Cosmetic Act? What specific materials create the greatest risk of a drug characterization?

2. If any of our products are characterized as drugs, does that characterization apply to all products in our catalog, or does it need to be analyzed product by product?

3. What changes to our marketing materials, customer service protocols, or product labeling would most meaningfully reduce the risk of a drug characterization?

Questions about New York Education Law section 6808:

4. Given our operational model, do you believe we are within the scope of New York Education Law section 6808, subdivision 1? Specifically, does our activity amount to offering drugs for sale at retail or wholesale in New York?

5. If section 6808 applies, which registration category, wholesaler, manufacturer, pharmacy, or outsourcing facility, is appropriate for our operations?

6. What are the eligibility requirements for that registration category, and do our current operations satisfy them?

7. What is the application process, and what documentation will we need to prepare?

Questions about nonresident operations:

8. We are located outside New York. Does section 6808-b require a separate nonresident registration for our operations? If so, what does that process look like?

9. Does the volume of our New York shipments affect the analysis, or is the registration obligation triggered by any level of sales activity?

Questions about enforcement and risk:

10. How actively is the section 6808 registration requirement enforced against ecommerce sellers? What does an enforcement action typically look like?

11. What are the penalties for operating without registration if registration is required?

12. If we determine that registration is required and we have been operating without it, what is the recommended approach for coming into compliance?

Questions about ongoing compliance:

13. What ongoing compliance obligations come with registration? Are there inspection requirements, record-keeping requirements, or reporting obligations?

14. How should we structure our customer service protocols to minimize the risk of creating an intended-use problem through customer communications?

15. Are there any other New York statutes or regulations, beyond section 6808, that apply to our operations?

For help finding an attorney who practices in this area, see our guide on finding a peptide business attorney.

How New York Fits Into the Broader State Compliance Picture

New York has a state-level drug registration statute in section 6808, and other states may have their own rules. The practical implication for a national ecommerce brand is that your compliance posture cannot be built around a single federal analysis. Each state where you have a meaningful volume of sales, or where you have a physical presence, needs its own analysis.

We have written separate guides for Florida, California, and Texas, and each state needs its own review. For New York, read section 6808 directly.

If you are building a national brand, the most efficient approach is to conduct the federal intended-use analysis once, rigorously, and then use that analysis as the foundation for each state-level review.

Our guide on peptide state business licensing provides a framework for thinking about multi-state compliance at a higher level, and our general guide on whether it is legal to sell peptides online covers the federal layer in more depth.

What Founders Get Wrong About the "Research Use Only" Label

We want to spend a dedicated section on this because it is the single most common misconception we encounter among founders who are new to this space. The belief is that a "research use only" label, combined with a disclaimer that the product is not for human use, creates a legal safe harbor. Do not rely on that belief. The regulation says: "The intent may be shown by such persons' expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article."

The same regulation applies here. The label is one thing to review, and your attorney can tell you how the rest is weighed.

Keep your label and your marketing consistent.

For a research peptide brand, this means that your label is the floor, not the ceiling, of your compliance obligation. You have to build your entire customer-facing operation around the same intended-use position that your label communicates. Every piece of copy, every email, every social media post, every customer service response has to be consistent with the research-use positioning. If any of those elements breaks from that positioning, you have created a gap between your label and your objective intent, and that gap is something to raise with your attorney.

This is also why we consistently recommend that founders invest in a legal review of their marketing materials before they launch, not after. See our guide on what "research use only" actually means for a full treatment of this topic.

Payments, Banking, and the New York Compliance Connection

One operational area that founders sometimes overlook is the connection between their regulatory compliance posture and their ability to access payment processing and banking services. We are not going to describe what card networks or banks weigh internally in their risk assessments, because those mechanisms are not public. What we can say is that payment processors set their own product rules, so read each one before you apply. WooPayments, for example, says that some business types and product types are not allowed to transact using WooPayments, and its list includes "Peptides and other research chemicals".

Keep your compliance documentation in order so you can answer any question a payment processor or bank puts to you. This is not a guarantee of any outcome. It is an observation about the value of having your compliance documentation in order before you need it.

The New York compliance question is one piece of that documentation. If you are shipping to New York, and a payment processor or bank asks about your regulatory compliance in New York, you want to have a clear, documented answer. That answer should include your intended-use analysis, your registration status or the legal basis for not registering, and your operational protocols for maintaining a consistent research-use positioning.

Operational Checklist for New York Compliance

The following checklist is designed to be used alongside the decision procedure above. It is not a substitute for legal advice. It is an operational tool for tracking the steps you need to complete.

Federal intended-use analysis:

• Conducted a written intended-use analysis for each product in the catalog
• Reviewed all website copy against the intended-use standard
• Reviewed all email marketing sequences against the intended-use standard
• Reviewed all social media content and engagement practices against the intended-use standard
• Established written customer service protocols for handling questions about human use
• Trained customer service team on those protocols
• Documented the intended-use analysis and stored it in a compliance file

New York drug registration analysis:

• Engaged a New York attorney to review section 6808 applicability
• Determined whether registration is required for your operational model
• If registration is required, identified the correct registration category
• If located outside New York, reviewed section 6808-b with your attorney
• Completed registration application if required, including the application fee (eight hundred twenty-five dollars for a wholesaler or manufacturer registration application)
• Stored registration documentation in a compliance file

Standard business formation and tax registration:

• Confirmed entity formation and any out-of-state registration with your attorney
• Confirmed with your accountant which sales tax registration applies, before making sales
• Stored all formation and registration documents in a compliance file

Ongoing compliance:

• Established a documented audit schedule for customer-facing materials
• Assigned a responsible team member to each audit
• Completed at least one full audit of all customer-facing materials
• Established a process for reviewing new marketing materials before publication
• Scheduled an annual legal review of compliance posture with your New York attorney

A Note on the Relationship Between State and Federal Enforcement

Founders sometimes ask whether they need to worry about New York enforcement if they are already compliant at the federal level. The safe approach is to ask your attorney, because federal compliance and New York compliance are separate questions. Section 6808 is a New York statute and 21 CFR 201.128 is a federal regulation, so each needs its own review.

Ask your attorney how enforcement works in practice, including what can start an inquiry.

This is not meant to create anxiety. It is meant to underscore that the state compliance question is real and independent, and that it deserves the same attention you give to your federal compliance posture.

For a broader overview of the federal layer, see our guide on whether it is legal to sell peptides online. For the state-level picture across multiple jurisdictions, see our guide on peptide state business licensing.

If you are building a research peptide brand and want to work through your New York compliance posture with us, we invite you to book a fit call at peptideecommerce.com. We are not attorneys and we do not give legal advice, but we can help you understand the operational landscape and connect you with the right resources.

Frequently Asked Questions

Do I need a license to sell peptides in New York?

The direct answer is: it depends on whether your products are characterized as drugs under federal intended-use law. If they are, ask your attorney whether New York Education Law section 6808 applies. It says no person shall possess drugs for certain purposes or offer drugs for sale at retail or wholesale "unless registered by the department as a pharmacy, wholesaler, manufacturer or outsourcing facility". If your products are not characterized as drugs, ask your attorney whether any other requirements apply. The characterization question requires a legal analysis of your specific products and marketing practices, not a general answer.

Does the "research use only" label protect me from New York's drug registration requirement?

Do not rely on it. As covered above, the regulation counts advertising and statements, not only the label. Review your website copy, email marketing, social media content, and customer service communications against that text with your attorney.

I am based in New Jersey and I ship to New York customers. Does section 6808 apply to me?

Potentially yes. New York Education Law section 6808-b covers the registration of nonresident establishments. If you are located outside New York but offering drugs for sale to New York customers, ask a New York attorney whether that provision applies to you.

What is the application fee for a wholesaler or manufacturer registration in New York?

New York Education Law section 6808 states that a wholesaler or manufacturer registration application is accompanied by a fee of eight hundred twenty-five dollars. This guide quotes only the application fee; read the current statute for any other fees. There may be other costs associated with registration, including legal fees and compliance costs, that your attorney will help you anticipate. Do not treat the application fee as the total cost of registration.

What happens if I have been selling into New York without registration and I find out I needed it?

This is a question for a New York attorney, not an operational guide. Ask your attorney how to approach coming into compliance before any enforcement action begins. Your attorney can advise you on the specific steps for coming into compliance and on how to approach the period during which you were operating without registration. Do not attempt to navigate this situation without legal counsel.

How does New York's drug registration requirement interact with my federal compliance obligations?

Treat them as separate questions. The federal starting point is 21 CFR 201.128, which refers to the objective intent of the persons legally responsible for the labeling of an article (or their representatives). The New York starting point is section 6808. Run both reviews.

Should I form my entity in New York or in another state if I am selling into New York?

This is a legal and tax question that your attorney and accountant should answer based on your specific situation. The entity formation decision has implications for liability, taxation, and operational structure that go beyond the drug registration question. Ask your attorney whether forming your entity in another state changes your New York filings or your analysis under section 6808. The entity formation decision and the drug registration decision are separate questions.

What other states have drug registration requirements similar to New York's?

We have not verified other states' registration rules in this article. See our Florida, California and Texas guides, linked above, and have an attorney review each state you ship to. Each state needs its own legal analysis rather than a single national answer.

Sources

New York Education Law section 6808: New York State Legislature, nysenate.gov (read 2026-10-12)

21 CFR 201.128, Meaning of "intended uses": Electronic Code of Federal Regulations, https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-B/section-201.128

New York Limited Liability Company Law section 203: New York State Legislature, https://www.nysenate.gov/legislation/laws/LLC/203

New York State Department of Taxation and Finance, Register as a sales tax vendor: https://www.tax.ny.gov/bus/st/register.htm

This article is not legal advice. Nothing in this guide creates an attorney-client relationship or substitutes for the advice of a licensed attorney in your jurisdiction.